Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check for the health industry. Their solution provides risk detection for multiple chronic diseases from a single blood sample. The Health Check can be scaled to entire populations at a low cost, replacing many current risk assessments. Detecting disease risks on a population level allows for effective targeting and tracking of health interventions and better prevention of chronic diseases. They operate globally with a parent company in Finland and subsidiaries in Japan, the United States, Singapore, and the United Kingdom, serving customers in more than 25 countries in healthcare and medical research sectors. Their technology is used in leading health initiatives such as the UK Biobank and validated by over 600 peer-reviewed publications.

Key milestones include listing on Nasdaq Helsinki Main Market in 2025, expansion to various countries including Japan and the US, launching direct-to-consumer services, acquiring intellectual property, and collaborations with notable partners such as Kaiser Foundation, ZOE, and 23andMe. They have won multiple awards and continue innovating in health technology.

The leadership team includes CEO and founder Teemu Suna, CTO and founder Antti Kangas, Chief Commercial Officers for APAC and EMEA, CFO, Chief R&D Officer, Chief Scientific Officer, COO, and laboratory and scientific directors among others.